Actively Recruiting
Randomized Study Comparing Bicalutamide to No Drug in Non-Muscle Invasive Bladder Cancer with Surgery
Led by University of Wisconsin, Madison · Updated on 2026-09-30
80
Participants Needed
6
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of bicalutamide, an androgen receptor inhibitor, on epidermal growth factor receptor EGFR protein expression in male patients with non-muscle invasive bladder cancer. This phase I trial compares bicalutamide to no study drug NSD to assess whether blocking androgen effects can influence EGFR expression, which is linked to bladder cancer progression. The study also explores various biomarkers and immune environment changes related to the disease and treatment. Participants are randomly assigned to one of two groups. One group receives bicalutamide orally once daily for up to 28 days before undergoing transurethral resection of bladder tumor TURBT on day 21. The other group receives no study drug but also undergoes TURBT on day 21. Throughout the study, patients provide blood and urine samples and may optionally have a tumor biopsy at baseline. The study includes detailed molecular and immunological assessments of tissue and urinary biomarkers. During the study, participants have regular sample collections and assessments to measure changes in EGFR expression and other markers before and after intervention. The primary outcome is the average EGFR expression level up to 28 days. Secondary and exploratory outcomes include androgen receptor levels, urinary biomarkers, immune microenvironment analysis, and genetic mutation studies. After completing treatment and surgery, patients are followed up 20 to 30 days later to monitor outcomes and safety.
CONDITIONS
Brief Title
A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here